Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

NCT02212925 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: BI 14332 CL
DRUG: Placebo

Sponsor

Boehringer Ingelheim